Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Cash from Operations (2016 - 2025)

IGC Pharma (IGC) has disclosed Cash from Operations for 16 consecutive years, with 2090000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Operations fell 109.84% to 2090000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was 5544000.0, a 14.05% decrease, with the full-year FY2025 number at 4795000.0, up 7.77% from a year prior.
  • Cash from Operations was 2090000.0 for Q3 2025 at IGC Pharma, down from 1407000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 526000.0 in Q1 2024 to a low of 2505000.0 in Q1 2021.
  • A 5-year average of 1605526.32 and a median of 1618000.0 in 2023 define the central range for Cash from Operations.
  • Peak YoY movement for Cash from Operations: skyrocketed 65.33% in 2024, then crashed 109.84% in 2025.
  • IGC Pharma's Cash from Operations stood at 2422000.0 in 2021, then surged by 31.96% to 1648000.0 in 2022, then rose by 3.7% to 1587000.0 in 2023, then grew by 17.01% to 1317000.0 in 2024, then crashed by 58.69% to 2090000.0 in 2025.
  • Per Business Quant, the three most recent readings for IGC's Cash from Operations are 2090000.0 (Q3 2025), 1407000.0 (Q2 2025), and 730000.0 (Q1 2025).